Developer docs
API playgroundTry for free, no card

Search company profiles

Oshen

Full company profile

uuid002gphx

Namestring
Oshen
Legal namestring
Oshen
Websiteurl
oshenbio.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Oshen is a private evergreen investment firm focused on the 'Better Ageing' sector, deploying capital into medtech and biotech companies that develop technologies to improve quality of life during the ageing process. The firm invests across the full spectrum from early-stage to market-ready companies, with a stated preference for IP-rich businesses whose technologies are patent-protected. Oshen partners globally with leading scientific institutions and companies to provide strategic benefit, value, and market access to its portfolio companies, and it works directly with founders and management teams on capital deployment, product development, and exit outcomes (M&A, IPOs, strategic collaborations).

The firm is led by Managing Partner Didier Cowling, a Cambridge-trained chemist and biochemist with 30+ years in life sciences, alongside partners Justin Cahill (Trinity College Dublin graduate with experience founding a Nasdaq-listed business in 2017) and Peter Wang (University of Toronto CS degree; Johns Hopkins MBA in Healthcare, Technology, and Innovation). The leadership team is distributed across Switzerland, Ireland, Luxembourg, and North America, with investment exposure spanning China, Ireland, Sweden, UK, Switzerland, and the Middle East. Oshen operates general offices in Switzerland and Luxembourg, and its primary public contact is info@oshenbio.com.

Oshen generates returns through capital appreciation on its portfolio investments rather than through product sales or licensing royalties. It does not disclose fund size, AUM, revenue, or specific portfolio companies. There are no disclosed products, SaaS offerings, APIs, or proprietary technology platforms — Oshen's core offering is patient capital, strategic operating support, and access to a global scientific and commercial network.

Short descriptiontext

Oshen is a private evergreen investment firm that deploys patient capital into IP-rich medtech and biotech companies focused on improving quality of life during ageing, working directly with founders and management teams globally.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences investing, medtech venture capital, biotech investment firm, better ageing innovation, evergreen investment vehicle
Industry1 code
PRIMARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Investment
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

As an evergreen investment vehicle, Oshen generates returns through capital appreciation, mergers and acquisitions, IPOs, and strategic collaborations with healthcare companies within their portfolio of medtech and biotech investments.

oshenbio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Oshen is an evergreen investment vehicle that deploys capital into medtech and biotech companies in the "Better Ageing" sector, from early-stage ventures to market-ready businesses with patent-protected technologies. Beyond providing funding, the firm partners with management teams to support product development from lab to market launch and assists with M&A, IPOs, and strategic healthcare collaborations. The firm pairs its investment capital with access to a global network of leading scientific institutions and companies to provide strategic benefit, value, and market access to portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Oshen is an evergreen investment firm focused on the 'Better Ageing' sector, investing in biotech and medtech innovations that improve quality of life as people age. The company deploys capital across early-stage to market-ready companies with IP-rich, patent-protected technologies. As an investment vehicle rather than a product company, Oshen does not offer distinct product modules or SaaS offerings — its core offering is investment capital, strategic support, and access to global partnerships for its portfolio companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Leading Scientific Institutions and Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Oshen partners globally with leading scientific institutions and companies working at the forefront of better ageing science. These partnerships offer strategic benefit, value and market access to their investment companies. They partner with organizations that share their vision and values of improving quality of life during ageing.

oshenbio.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused crossover fund investing across public and private biotech. Comparable as a science-driven, IP-focused investor with deep biotech domain expertise and multi-stage deployment.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private and public markets. Comparable as a globally focused, life sciences-specialised investment platform with multi-stage capabilities.

TypeBroad incumbent
Description

Large diversified venture firm with material life sciences exposure. Comparable as a science-led investor in IP-rich biotech and medtech, though significantly larger and broader in scope than Oshen's focused Better Ageing mandate.

TypeDirect peer
Description

Venture firm investing in early-stage longevity and biotech companies. Highly comparable to Oshen's Better Ageing thesis as a focused, science-led investor in human longevity and ageing-related therapeutics.

TypeDirect peer
Description

Longevity-focused venture fund targeting ageing biology and age-related disease. Highly comparable as a small, science-driven, thematic investor focused on the Better Ageing space.

TypeDirect peer
Description

Long-tenured US venture firm investing in early-stage biotech and deep tech companies. Directly comparable as a science-driven, IP-rich, early-to-growth stage life sciences investor with operational involvement.

TypeDirect peer
Description

Longevity-focused biotech holding company building and investing in therapies targeting ageing. Comparable to Oshen as an evergreen-style, IP-rich investor focused exclusively on the Better Ageing / longevity thesis.

TypeDirect peer
Description

Early-stage biotech venture firm that builds companies from inception through clinical development. Comparable as a science-led, IP-focused, early-to-mid stage biotech investor with operational involvement.

TypeDirect peer
Description

Biotech creation and venture firm that originates and builds breakthrough life sciences companies. Comparable to Oshen as a deep-science, IP-rich, hands-on investor across the biotech product life cycle.

TypeDirect peer
Description

Healthcare-focused venture firm investing across biotech, medtech, and healthcare services. Comparable as a multi-stage, IP-rich investor with deep scientific networks and global deal sourcing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oshen

Life Sciences Investmentoshenbio.com

Oshen is a private evergreen investment firm that deploys patient capital into IP-rich medtech and biotech companies focused on improving quality of life during ageing, working directly with founders and management teams globally.

What Oshen does

Oshen is a private evergreen investment firm focused on the 'Better Ageing' sector, deploying capital into medtech and biotech companies that develop technologies to improve quality of life during the ageing process. The firm invests across the full spectrum from early-stage to market-ready companies, with a stated preference for IP-rich businesses whose technologies are patent-protected. Oshen partners globally with leading scientific institutions and companies to provide strategic benefit, value, and market access to its portfolio companies, and it works directly with founders and management teams on capital deployment, product development, and exit outcomes (M&A, IPOs, strategic collaborations).

The firm is led by Managing Partner Didier Cowling, a Cambridge-trained chemist and biochemist with 30+ years in life sciences, alongside partners Justin Cahill (Trinity College Dublin graduate with experience founding a Nasdaq-listed business in 2017) and Peter Wang (University of Toronto CS degree; Johns Hopkins MBA in Healthcare, Technology, and Innovation). The leadership team is distributed across Switzerland, Ireland, Luxembourg, and North America, with investment exposure spanning China, Ireland, Sweden, UK, Switzerland, and the Middle East. Oshen operates general offices in Switzerland and Luxembourg, and its primary public contact is info@oshenbio.com.

Oshen generates returns through capital appreciation on its portfolio investments rather than through product sales or licensing royalties. It does not disclose fund size, AUM, revenue, or specific portfolio companies. There are no disclosed products, SaaS offerings, APIs, or proprietary technology platforms — Oshen's core offering is patient capital, strategic operating support, and access to a global scientific and commercial network.

Oshen firmographics

Firmographics
Name
Oshen
Legal name
Oshen
Website
https://oshenbio.com
Company type
Private
Operating status
Operating
Short description
Oshen is a private evergreen investment firm that deploys patient capital into IP-rich medtech and biotech companies focused on improving quality of life during ageing, working directly with founders and management teams globally.
Ownership category
akta.pro rank

Oshen industry classification

Industry
Product category
Life Sciences Investment
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Life sciences investing
  • Medtech venture capital
  • Biotech investment firm
  • Better ageing innovation
  • Evergreen investment vehicle

Oshen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Investment Returns: As an evergreen investment vehicle, Oshen generates returns through capital appreciation, mergers and acquisitions, IPOs, and strategic collaborations with healthcare companies within their portfolio of medtech and biotech investments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Oshen product offering

Product offering

Core offering

Oshen is an evergreen investment vehicle that deploys capital into medtech and biotech companies in the "Better Ageing" sector, from early-stage ventures to market-ready businesses with patent-protected technologies. Beyond providing funding, the firm partners with management teams to support product development from lab to market launch and assists with M&A, IPOs, and strategic healthcare collaborations. The firm pairs its investment capital with access to a global network of leading scientific institutions and companies to provide strategic benefit, value, and market access to portfolio companies.

Product overview

Oshen is an evergreen investment firm focused on the 'Better Ageing' sector, investing in biotech and medtech innovations that improve quality of life as people age. The company deploys capital across early-stage to market-ready companies with IP-rich, patent-protected technologies. As an investment vehicle rather than a product company, Oshen does not offer distinct product modules or SaaS offerings — its core offering is investment capital, strategic support, and access to global partnerships for its portfolio companies.

Differentiator

Problem solved

Functional benefit

Companies that use Oshen

Customer profile

Segments2 records

Ideal customer profiles1 record

Oshen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Oshen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Leading Scientific Institutions and CompaniescoreStrategic or Co-development PartnerOshen partners globally with leading scientific institutions and companies working at the forefront of better ageing science. These partnerships offer strategic benefit, value and market access to their investment companies. They partner with organizations that share their vision and values of improving quality of life during ageing.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Oshen competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: Healthcare-focused crossover fund investing across public and private biotech. Comparable as a science-driven, IP-focused investor with deep biotech domain expertise and multi-stage deployment.
  • OrbiMed: Healthcare-dedicated investment firm across private and public markets. Comparable as a globally focused, life sciences-specialised investment platform with multi-stage capabilities.
  • LongeVC: Venture firm investing in early-stage longevity and biotech companies. Highly comparable to Oshen's Better Ageing thesis as a focused, science-led investor in human longevity and ageing-related therapeutics.
  • Apollo Ventures: Longevity-focused venture fund targeting ageing biology and age-related disease. Highly comparable as a small, science-driven, thematic investor focused on the Better Ageing space.
  • ARCH Venture Partners: Long-tenured US venture firm investing in early-stage biotech and deep tech companies. Directly comparable as a science-driven, IP-rich, early-to-growth stage life sciences investor with operational involvement.
  • Juvenescence: Longevity-focused biotech holding company building and investing in therapies targeting ageing. Comparable to Oshen as an evergreen-style, IP-rich investor focused exclusively on the Better Ageing / longevity thesis.
  • Atlas Venture: Early-stage biotech venture firm that builds companies from inception through clinical development. Comparable as a science-led, IP-focused, early-to-mid stage biotech investor with operational involvement.
  • Flagship Pioneering: Biotech creation and venture firm that originates and builds breakthrough life sciences companies. Comparable to Oshen as a deep-science, IP-rich, hands-on investor across the biotech product life cycle.
  • Versant Ventures: Healthcare-focused venture firm investing across biotech, medtech, and healthcare services. Comparable as a multi-stage, IP-rich investor with deep scientific networks and global deal sourcing.

Broad incumbents

  • Khosla Ventures: Large diversified venture firm with material life sciences exposure. Comparable as a science-led investor in IP-rich biotech and medtech, though significantly larger and broader in scope than Oshen's focused Better Ageing mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Oshen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oshen leadership team

Management profile

Number of profiles

Profiles3 records

Oshen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oshen M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oshen

What does Oshen do?

Oshen is an evergreen investment vehicle that deploys capital into medtech and biotech companies in the "Better Ageing" sector, from early-stage ventures to market-ready businesses with patent-protected technologies. Beyond providing funding, the firm partners with management teams to support product development from lab to market launch and assists with M&A, IPOs, and strategic healthcare collaborations. The firm pairs its investment capital with access to a global network of leading scientific institutions and companies to provide strategic benefit, value, and market access to portfolio companies.

Is Oshen a public or private company?

Oshen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oshen founded?

Oshen was founded in -1.

How does Oshen make money?

One revenue line is on record: investment Returns.

Who are Oshen's main competitors?

Direct peers on record are RA Capital Management, OrbiMed, LongeVC, Apollo Ventures, ARCH Venture Partners, Juvenescence, Atlas Venture, Flagship Pioneering and Versant Ventures. Khosla Ventures is listed as a broad incumbent.

Does Oshen have an API?

No public API is recorded for Oshen.

What industry is Oshen in?

Oshen's product category is Life Sciences Investment. Its primary akta.pro industry code is FSANAGAG, Endowment / OCIO-Style Multi-Manager Platforms. Its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Healome Therapeutics Raises £2 Million Seed Round To Advance Eye-Drop Matrix Technology For Ocular Surface DiseasesHealome Therapeutics, a University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases, has raised an oversubscribed £2 million seed funding round led by Empirical Ventures with participation from DEBRA Research, Cure EB, Oshen Bio, and SFC Capital. The capital will advance preclinical development, scale manufacturing, engage with regulators including the UK’s MHRA and the U.S. FDA, and prepare for first-in-human clinical studies expected in 2027. The company estimates the dry eye disease market alone exceeds $5 billion globally and is targeting conditions including ocular surface inflammation, corneal injuries, and ocular complications associated with Epidermolysis Bullosa.MorningstarHealome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface DiseasesHealome Therapeutics closed a £2 million oversubscribed seed round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio, and SFC Capital. The funds will support pre-clinical development and first-in-human studies expected in 2027. The company's eye-drop matrix technology aims to improve drug retention on the ocular surface.European BiotechnologyScarlet raises £3.2 million to advance lab-grown red blood cell therapiesScarlet Therapeutics, a British biotech company, has raised £3.2 million (€3.7 million) in seed funding to advance its lab-grown red blood cell therapies, with the round led by Eos Advisory and joined by Oshen Bio, Daft Capital, and existing backer SCVC. The company's approach uses immortalized cell lines to generate red blood cells, addressing scalability and reproducibility challenges that have hindered competitors relying on donor-derived cells, and preclinical studies demonstrated their lab-grown cells achieved comparable half-lives to donated RBCs. The funding will support animal studies in three indications, including hyperammonemia and hyperoxaluria, as Scarlet works toward selecting a lead program and advancing toward clinical development.The EconomistEarth’s climate is approaching irreversible tipping pointsBritain's Advanced Research and Invention Agency (ARIA) announced a £81m, five-year programme in February to fund 26 teams developing an early warning system for climate tipping points, focusing specifically on the Greenland ice sheet and subpolar gyre. Companies including Oshen and Marble are deploying technologies such as underwater drones, self-sailing robots, and surface monitoring robots to collect data on ice melt and ocean currents, while the British Antarctic Survey is co-leading research efforts targeting the Greenland ice sheet. Scientists estimate current global temperatures are 1.2°C above pre-industrial levels, with tipping points for events like Amazon dieback projected to occur between 2°C and 6°C of warming, though the exact thresholds remain uncertain due to model limitations.Uktechnews4D Medicine (t/a 4D Biomaterials) secures £3.4 Million Series A Investment led by Oshen Holdings4D Medicine raised £3.4m in a Series A led by Oshen Holdings, with backing from DSW Ventures, SFC Capital, and others. The funds will complete pre-clinical testing of its first product range and seek FDA clearance for the US market. The company plans to raise a Series B early next year.startupticker.chOshen supports Topadur in the development of a treatment for alopeciaTopadur Pharma AG and Oshen Holdings SA have entered a co-development and licensing agreement for TOP-M119, a drug candidate for treating alopecia, granting Oshen commercialization rights in Greater China. As part of the deal, Oshen will invest CHF 3 million upfront with an additional CHF 12 million in milestone payments to cover estimated development costs.